CA2375854A1 - Novel liposomal vector complexes and their use in gene therapy - Google Patents

Novel liposomal vector complexes and their use in gene therapy Download PDF

Info

Publication number
CA2375854A1
CA2375854A1 CA002375854A CA2375854A CA2375854A1 CA 2375854 A1 CA2375854 A1 CA 2375854A1 CA 002375854 A CA002375854 A CA 002375854A CA 2375854 A CA2375854 A CA 2375854A CA 2375854 A1 CA2375854 A1 CA 2375854A1
Authority
CA
Canada
Prior art keywords
complex
component
liposomal vector
vector complex
liposomal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375854A
Other languages
English (en)
French (fr)
Inventor
Sabine Brusselbach
Kristina Muller
Alfred Fahr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectron Therapeutics AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375854A1 publication Critical patent/CA2375854A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002375854A 1999-06-02 2000-05-23 Novel liposomal vector complexes and their use in gene therapy Abandoned CA2375854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19925143.6 1999-06-02
DE19925143A DE19925143A1 (de) 1999-06-02 1999-06-02 Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie
PCT/EP2000/004678 WO2000074646A2 (de) 1999-06-02 2000-05-23 Neue liposomale vektorkomplexe und deren verwendung für die gentherapie

Publications (1)

Publication Number Publication Date
CA2375854A1 true CA2375854A1 (en) 2000-12-14

Family

ID=7909923

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375854A Abandoned CA2375854A1 (en) 1999-06-02 2000-05-23 Novel liposomal vector complexes and their use in gene therapy

Country Status (6)

Country Link
EP (1) EP1187929A2 (de)
JP (1) JP2003501373A (de)
AU (1) AU4758300A (de)
CA (1) CA2375854A1 (de)
DE (1) DE19925143A1 (de)
WO (1) WO2000074646A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT103865A (pt) * 2007-10-25 2009-05-15 Univ De Coimbra Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção
CN101270168B (zh) * 2008-05-13 2011-06-22 中国药科大学 透明质酸接枝聚乙烯亚胺共聚物、制备方法及其作为基因载体的应用
EP3538546A1 (de) 2016-11-14 2019-09-18 Novartis AG Zusammensetzungen, verfahren und therapeutische verwendungen im zusammenhang mit fusogenem protein minion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
EP0784984B1 (de) * 1996-01-17 2003-07-02 F. Hoffmann-La Roche Ag Transfektionskompetente Moleküle
JP2002511851A (ja) * 1997-04-30 2002-04-16 リージェンツ オブ ジ ユニバーシティー オブ ミネソタ 肝細胞の遺伝的病変を修正するためのリコンビナジェニックオリゴヌクレオ塩基のｉｎ ｖｉｖｏでの使用
WO1999051629A2 (de) * 1998-04-07 1999-10-14 Roche Diagnostics Gmbh New compounds
WO2000003683A2 (en) * 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof

Also Published As

Publication number Publication date
AU4758300A (en) 2000-12-28
JP2003501373A (ja) 2003-01-14
WO2000074646A2 (de) 2000-12-14
WO2000074646A3 (de) 2001-08-09
EP1187929A2 (de) 2002-03-20
DE19925143A1 (de) 2000-12-07

Similar Documents

Publication Publication Date Title
Harris et al. Tissue-specific gene delivery via nanoparticle coating
Pichon et al. Histidine-rich peptides and polymers for nucleic acids delivery
US20030045465A1 (en) Histidine copolymer and methods for using same
US20080171025A1 (en) Highly Branched Hk Peptides as Effective Carriers of Sirna
US6245427B1 (en) Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
MX2014004415A (es) Bicapas lipidicas soportadas por nanoparticulas porosas (protecelulas) para suministro dirigido, incluido el suministro transdermico de carga, y los metodos relacionados.
JP2003528131A (ja) カチオン性リポソーム
WO1997000965A2 (en) A lipidic vector for nucleic acid delivery
JP2003503370A (ja) 核酸を細胞に導入するための配合剤
US6372720B1 (en) Liposome fusion and delivery vehicle
US20050163832A1 (en) Intracellular delivery of therapeutic agents
US20210170046A1 (en) Improved lipid-peptide nanocomplex formulation for mrna delivery to cells
WO2013140643A1 (ja) 機能性タンパク質を細胞内に送達するためのキャリア
JP2003507348A (ja) 標的設定人工遺伝子送達
US11793756B2 (en) Anionic nanocomplexes for nucleic acid delivery
WO2023093596A1 (zh) 一种用于有效递送核酸的环状多肽载体及其变化形式
JP2003514843A (ja) モジュラー標的化リポソーム送達システム
CA2375854A1 (en) Novel liposomal vector complexes and their use in gene therapy
JP2008031142A (ja) 脂肪組織標的化ペプチド及び該ペプチドを有するリポソーム
Bansal Non-viral vectors for gene delivery
WO2011074578A1 (ja) 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体
WO2024181580A1 (ja) 脂質ナノ粒子、医薬組成物、および脂質ナノ粒子の製造方法
JP2006514924A (ja) 走触性ペプチドを含むリポソーム組成物及びその使用
US20230233476A1 (en) Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index
US20230121879A1 (en) Methods for preparing nanoparticle compositions containing histidine-lysine copolymers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead